Biogen’s CEO Chris Vibacher said ‘a new Biogen’ is emerging following the end of its multiple sclerosis treatments heyday.

US biotech major Biogen (Nasdaq: BIIB) reported stronger-than-expected earnings for the first quarter of 2025, helped by ...

Alongside Skyclarys, Biogen’s rare disease business is headed by spinal muscular atrophy treatment Spinraza (nusinersen). Spinraza generated global Q1 2025 sales of $423.9m, up from $341.3m in ...

Cost-effectiveness body NICE has rejected Biogen’s Spinraza (nusinersen) therapy for the rare genetic muscle wasting disease spinal muscular atrophy (SMA) because of its high cost – but is in ...

and Tysabri (natalizumab), as well as blockbuster spinal muscular atrophy therapy Spinraza (nusinersen). Biogen will retain its commercial rights to the biosimilars already brought to market ...

Management believes its ability to improve motor function over time is superior to its gene therapy rivals and provides supporting data—outperformance over nusinersen—as per the slide below ...

The Ono deal, expansion of its agreement with its partnership with Sobi for olezarsen ex-U.S., and a Fast Track designation handed to Ionis / Biogen's AD drug may all add a positive sheen to Q1 ...

The original drug was developed by the American biopharmaceutical company Biogen. There is also an analog of nucinersen marketed in Russia as Lantesens. It was registered by Generium. A record of ...